146 related articles for article (PubMed ID: 30026450)
1. [A Case of Drug-Induced Organizing Pneumonia Caused by Dasatinib].
Sato M; Watanabe S; Aoki N; Asakawa K; Moriyama H; Oshima Y; Koya T; Okazuka K; Kikuchi T
Gan To Kagaku Ryoho; 2018 May; 45(5):851-854. PubMed ID: 30026450
[TBL] [Abstract][Full Text] [Related]
2. [Reversible dasatinib-related pulmonary arterial hypertension in a CML patient].
Nagasaki J; Aoyama Y; Nomoto Y; Ido K; Ichihara H; Mugitani A
Rinsho Ketsueki; 2016 May; 57(5):618-23. PubMed ID: 27263788
[TBL] [Abstract][Full Text] [Related]
3. Dasatinib-induced Reversible Demyelinating Peripheral Neuropathy and Successful Conversion to Nilotinib in Chronic Myelogenous Leukemia.
Inoue H; Taji H; Yamada K; Iriyama C; Saito T; Kato H; Yanada M; Yamamoto K; Matsukawa N
Intern Med; 2020 Oct; 59(19):2419-2421. PubMed ID: 32611965
[TBL] [Abstract][Full Text] [Related]
4. [Development of pulmonary arterial hypertension during oral dasatinib therapy for chronic myelogenous leukemia].
Morishita S; Hagihara M; Itabashi M; Ishii Y; Yamamoto W; Numata A; Motohashi K; Matsumoto K; Fujisawa S; Nakajima H
Rinsho Ketsueki; 2016 Aug; 57(8):999-1003. PubMed ID: 27599415
[TBL] [Abstract][Full Text] [Related]
5. Dasatinib-induced Nonspecific Interstitial Pneumonia That Developed 7 Years after the Initiation of Dasatinib.
Takekoshi D; Matsui Y; Akutsu T; Nishioka A; Kiritani A; Okuda K; Watanabe J; Miyagawa H; Utsumi H; Hashimoto M; Wakui H; Minagawa S; Hara H; Numata T; Noda Y; Makishima R; Ikegami M; Kawabata Y; Araya J; Kuwano K
Intern Med; 2020 Sep; 59(18):2297-2300. PubMed ID: 32536651
[TBL] [Abstract][Full Text] [Related]
6. Reversible Pulmonary Arterial Hypertension Associated with Dasatinib for Chronic Myeloid Leukemia.
Hong JH; Lee SE; Choi SY; Kim SH; Jang EJ; Bang JH; Park JE; Jeon HR; Oh YJ; Yi JE; Jung HO; Youn HJ; Kim DW
Cancer Res Treat; 2015 Oct; 47(4):937-42. PubMed ID: 25648097
[TBL] [Abstract][Full Text] [Related]
7. Severe pleural effusion associated with nilotinib for chronic myeloid leukaemia: cross-intolerance with tyrosine kinase inhibitors.
Satoh K; Morisawa S; Okuyama M; Nakae H
BMJ Case Rep; 2021 Sep; 14(9):. PubMed ID: 34479888
[TBL] [Abstract][Full Text] [Related]
8. Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase: Identification and Management.
Cortes JE; Jimenez CA; Mauro MJ; Geyer A; Pinilla-Ibarz J; Smith BD
Clin Lymphoma Myeloma Leuk; 2017 Feb; 17(2):78-82. PubMed ID: 28082112
[TBL] [Abstract][Full Text] [Related]
9. Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity.
Schiffer CA; Cortes JE; Hochhaus A; Saglio G; le Coutre P; Porkka K; Mustjoki S; Mohamed H; Shah NP
Cancer; 2016 May; 122(9):1398-407. PubMed ID: 26998677
[TBL] [Abstract][Full Text] [Related]
10. Is dasatinib-related pulmonary hypertension a clinical concern?
Szmit S
Future Oncol; 2015 Sep; 11(18):2491-4. PubMed ID: 26278893
[No Abstract] [Full Text] [Related]
11. Dasatinib for chronic myelogenous leukemia improves skin symptoms of systemic sclerosis.
Arai K; Yoshifuji K; Motomura Y; Sonokawa S; Suzuki S; Kumagai T
Int J Hematol; 2019 Jun; 109(6):718-722. PubMed ID: 30788724
[TBL] [Abstract][Full Text] [Related]
12. Human herpesvirus 8-unrelated primary effusion lymphoma-like lymphoma following tyrosine kinase inhibitor treatment for chronic myelogenous leukemia.
Kojima M; Nakamura N; Amaki J; Numata H; Miyaoka M; Motoori T; Matsumoto K; Ando K
J Clin Exp Hematop; 2017; 57(2):69-73. PubMed ID: 29021516
[TBL] [Abstract][Full Text] [Related]
13. A 68-Year-Old Man With Chronic Myelogenous Leukemia and a Large Unilateral Pleural Effusion.
Alter A; Chaisson N; Mukherjee S; Gildea T
Chest; 2018 Feb; 153(2):e33-e36. PubMed ID: 29406237
[TBL] [Abstract][Full Text] [Related]
14. Dasatinib-associated reversible demyelinating peripheral polyneuropathy in a case of chronic myeloid leukemia.
Ishida T; Akagawa N; Miyata T; Tominaga N; Iizuka T; Higashihara M; Suzuki T; Miyazaki K
Int J Hematol; 2018 Mar; 107(3):373-377. PubMed ID: 29027647
[TBL] [Abstract][Full Text] [Related]
15. The efficacy of tolvaptan in treating dasatinib-induced pleural effusions in patients with chronic myelogenous leukemia.
Aoyama R; Ishikawa J; Harada K
J Cardiol; 2020 Feb; 75(2):203-207. PubMed ID: 31416783
[TBL] [Abstract][Full Text] [Related]
16. [Mixed connective tissue disease with pulmonary hypertension developing in a chronic myeloid leukemia patient on dasatinib treatment].
Watanuki S; Kikuchi T; Toyama T; Abe R; Nakayama H; Karigane D; Shimizu T; Kikuchi J; Matsumoto K; Yasuoka H; Kataoka M; Okamoto S; Mori T
Rinsho Ketsueki; 2018; 59(2):174-177. PubMed ID: 29515069
[TBL] [Abstract][Full Text] [Related]
17. [Chronic myeloid leukemia complicated by pulmonary hypertension during dasatinib therapy: a single-center retrospective study].
Edahiro Y; Takaku T; Konishi H; Tsukune Y; Fujioka I; Takasu K; Gotoh A; Daida H; Komatsu N
Rinsho Ketsueki; 2017; 58(11):2213-2218. PubMed ID: 29212971
[TBL] [Abstract][Full Text] [Related]
18. Cross-Intolerance With Dasatinib Among Imatinib-Intolerant Patients With Chronic Phase Chronic Myeloid Leukemia.
Khoury HJ; Goldberg SL; Mauro MJ; Stone RM; Deininger MW; Bradley-Garelik MB; Mohamed H; Guilhot F
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):341-349.e1. PubMed ID: 27133948
[TBL] [Abstract][Full Text] [Related]
19. Lupus-like symptoms with anti-RNP/Sm and anti-nuclear antibodies positivity: An extremely rare adverse event of dasatinib.
Maral S; Bakanay SM; Kucuksahin O; Dilek I
J Oncol Pharm Pract; 2020 Apr; 26(3):738-741. PubMed ID: 31359838
[TBL] [Abstract][Full Text] [Related]
20. [Repeated partially reversible pulmonary arterial hypertension related to dasatinib: a case report and literature review].
Jin J; Xu XM; Wang C
Zhonghua Jie He He Hu Xi Za Zhi; 2016 Feb; 39(2):83-7. PubMed ID: 26879609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
